Robert Iannone - 18 Jun 2021 Form 4 Insider Report for Jounce Therapeutics, Inc.

Role: Director
Signature: /s/ Caroline Gammill, Attorney-in-fact
Issuer symbol: N/A
Transactions as of: 18 Jun 2021
Net transactions value: $0
Form type: 4
Filing time: 22 Jun 2021, 16:47:35 UTC
Previous filing: 21 Jun 2021
Next filing: 09 Mar 2022
SEC: View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	JNCE	Stock Option (Right to Buy)	Award	$0	+15,700		$0.000000	15,700	18 Jun 2021	Common Stock	15,700	$7.27	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2022 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors.

Content

The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2022 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors.